ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Menlo Therapeutics Inc

Menlo Therapeutics Inc (MNLO)

1.35
0.00
(0.00%)
Cerrado 01 Diciembre 3:00PM
0.00
0.00
(0.00%)
Fuera de horario: -

Su centro para precios en tiempo real, ideas y debates en vivo

Estadísticas y detalles clave

Último Precio
1.35
Postura de Compra
1.36
Postura de Venta
1.37
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
Precio Anterior
1.35
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
13,957,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.45
Beneficio por acción (BPA)
-2.04
turnover
424k
Beneficio neto
-28.45M

Acerca de Menlo Therapeutics Inc

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sede
Wilmington, Delaware, USA
Fundado
-

MNLO Últimas noticias

Robbins Geller Rudman & Dowd LLP Announce Proposed Settlement in the Menlo Therapeutics Inc. Securities Settlement

The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Menlo Therapeutics Inc. Securities Settlement: SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF...

Menlo Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

REDWOOD CITY, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the...

Menlo Therapeutics Announces Results from Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

REDWOOD CITY, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced results from its Phase 2 clinical trial...

Menlo Therapeutics to Host Conference Call Tomorrow to Discuss Results from Phase 2 Trial of Serlopitant in Patients with Chr...

REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast...

Menlo Therapeutics Announces Publication of Phase 2 Results for Serlopitant for the Treatment of Pruritus Associated with Pso...

REDWOOD CITY, Calif., Feb. 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment...

Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd. PR Newswire NEW YORK, Nov. 12, 2019 NEW YORK, Nov. 12, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible...

Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates

REDWOOD CITY, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment...

Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis

- Pivotal results expected in March/April 2020 - - Details of the program to be reviewed at company’s Investor Day today in NY - REDWOOD CITY, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Menlo...

Menlo Therapeutics to Host Investor Day October 29, 2019

-Management to Review Late Stage Development, NDA-readiness and Commercial Opportunity of Serlopitant- -Discussion to Feature two Prominent Key Opinion Leaders Well Versed in the Unmet Needs of...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BSLKBolt Projects Holdings Inc
US$ 0.71
(139.86%)
80.07M
PRZOParaZero Technologies Ltd
US$ 1.24
(94.14%)
202.48M
AIEVThunder Power Holdings Inc
US$ 0.47
(87.25%)
122.71M
PASGPassage Bio Inc
US$ 1.13
(69.52%)
15.43M
EPOWSunrise New Energy Company Ltd
US$ 1.06
(45.21%)
314.9k
APLTApplied Therapeutics Inc
US$ 2.03
(-76.31%)
43.9M
TGLTreasure Global Inc
US$ 0.2944
(-29.08%)
1.85M
PROCProcaps Group SA
US$ 1.51
(-27.75%)
106.08k
SHOTWSafety Shot Inc
US$ 0.104
(-20.00%)
1.43k
MONDMondee Holdings Inc
US$ 0.7102
(-19.59%)
297.63k
PRZOParaZero Technologies Ltd
US$ 1.24
(94.14%)
202.48M
NVDANVIDIA Corporation
US$ 138.25
(2.15%)
140.34M
AIEVThunder Power Holdings Inc
US$ 0.47
(87.25%)
122.71M
RGTIRigetti Computing Inc
US$ 3.05
(27.08%)
115.6M
MARAMARA Holdings Inc
US$ 27.42
(1.86%)
88.39M
Juntao Juntao 4 minutos hace
$AUTR
https://www.stockscores.com/chart.asp?TickerSymbol=AUTR&TimeRange=1095&Interval=w&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=&Band=&avgType1=&movAvg1=&avgType2=&movAvg2=&Indicator1=None&Indicator2=None&Indicator3=None&Indicator4=None&endDate=&C
AUTR
shajandr shajandr 7 minutos hace
To Whom It May CONcern: MGTI is nuffin butt a LADD/HONIG/FIFE scam.
MGTI
biosectinvestor biosectinvestor 10 minutos hace
Ah; you're just talking off label for an already approved oncology drug.

You seem to forget that the 21st Century Cures Act is all about making those drugs not just broadly available to a broader array of patients and conditions asap, but also getting insurance coverage even if the dr
NWBO
biosectinvestor biosectinvestor 12 minutos hace
This is not true. Too many people I know go for experimental treatments overseas including people I know really can't afford it but somehow get the money together and most of those treatments are untried and a waste of money. I have known too many people who, being diagnosed with serious, life threa
NWBO
devil dog 96 devil dog 96 12 minutos hace
The shares I got on the BID @ .30 were sold when we got the freak bonus POP to 98 cents in 2020. I started reloading after the bear raid started. My average is under .06 now because I was smart enough to BID sit the past year and collect what ever shares you no proof scam theory promoter clowns
ATMH
jeunke22 jeunke22 25 minutos hace
You are correct. Apparently a double count put it at 44 mio in the Fintel reporting early November, but it was corrected to 40 mio. Up from 33,7 mio per 09/30 to 40 mio as of November.
LWLG
infamous infamous 32 minutos hace
Right
SFIO
Richie R Richie R 33 minutos hace
Looking for a winner here!
nowwhat2 nowwhat2 37 minutos hace
https://investorshub.advfn.com/uimage/uploads/2024/12/1/oozwgXRP_111111_30_5d_730pm_news_event_Q_TA.jpg



https://investorshub.advfn.com/uimage/uploads/2024/12/1/nszyaXRP_111111_30_5d_10pm_news_event_Q_TA.jpg




5 HOURS EARLIER ;
XRPUSD
cash-talks-bs-walks cash-talks-bs-walks 46 minutos hace
Time to make some $$$$$$$
PGHL
cb521 cb521 48 minutos hace
In His Time. Very excited at what’s happening, not hoping for anything. Chilling
ZNOG
CorsairNavigator20 CorsairNavigator20 54 minutos hace
Just my thoughts are the phase 1 data could drive us to $250M. Phase2 would not be completed in 2025 and I would be hoping 500-750M. The real driver would be the pancreatic cancer study next year. That phase 1 data could drive it since the study group could have 3-6 months to end of life. I look
MRKR
nowwhat2 nowwhat2 1 hora hace
You LIKE our new CEO ?.....I dunno.....
I had to fix her hair ;
https://www.news-journal.com/international-battery-metals-ibat-announces-iris-jancik-takes-helm-as-ceo-to-lead-expansion-of/article_3a9f211a-8b57-5c12-beb5-d202cf389a6a.html

https://investorshub.advfn.com/
IBATF
RichieBoy RichieBoy 1 hora hace
Are you trying to establish the premise that OTCN has stopped screwing over Retail. Or is this pure speculation. 🤹
AFFU
XMaster2023 XMaster2023 1 hora hace
RobotDroid,
Speaking of GIGO, you win.
NWBO
FrostyStar1 FrostyStar1 1 hora hace
Well lets see, the only time Ukraine didn't get smaller was when Trump was in the White House. Obama gave Putin Crimea and Biden let Putin take Eastern Ukraine.

The only time North Korea wasn't firing off rockets was when Trump was president.

Biden abandoned 11 embassi
STHC
RichieBoy RichieBoy 1 hora hace
Has Bjarne delineated any so called strategic alternatives yet?
SONXD
Stock_Barber Stock_Barber 1 hora hace
Full stream ahead

Yes Indeed!

https://external-content.duckduckgo.com/iu/?u=https%3A%2F%2Fsc01.alicdn.com%2Fkf%2FHTB1P8EOSXXXXXX9XVXXq6xXFXXXC%2F230436576%2FHTB1P8EOSXXXXXX9XVXXq6xXFXXXC.jpg&f=1&nofb=1&ipt=7b24b84b96f71b702016fae9367c98caa7215a646b3621ab4f1f5c6ca645812c
DBMM

Su Consulta Reciente

Delayed Upgrade Clock